Daniel M. Houde

Daniel M. Houde has extensive experience in the pharmaceutical industry. Daniel M. is currently work as a Senior Director of Clinical Quality Assurance at Biorasi, starting in 2023. Prior to this, they worked as a Director of Quality Assurance at IQVIA Canada from 2022 to 2023. From 2019 to 2022, they served as a Director of Development Quality Assurance at Novartis. Before that, they held the position of Senior Director of Clinical Studies at Medicago from 2018 to 2019. Daniel M. also worked as the Head of Clinical Compliance and Training at Seqirus in 2017, the Head of Quality Assurance and Compliance at Cara Therapeutics from 2016 to 2017, and the Senior Director of Regulatory Policy and Compliance at Covance from 2015 to 2016. Prior to that, they worked in various roles at ARIAD Pharmaceuticals, Inc., Alexion Pharmaceuticals, and Quintiles.

Daniel M. Houde has a diverse education history. Daniel M. obtained a Bachelor of Science in Biochemistry from the Université du Québec à Trois-Rivières in 1980. Daniel M. then attended the Institut Armand-Frappier from 1980 to 1983 but did not complete their Master's degree in Virology. Houde pursued further education and earned an LL.B. in Law from UQAM | Université du Québec à Montréal from 1992 to 1998. During the same period, they also completed a two-year program, obtaining an M.B.A. in Management. In 2012, they attended Villanova University to study Six Sigma, and in 2023, they completed a Certificate in Computer Science specializing in Modeling, Analysis, and Database from Université Laval. Houde has recently been pursuing further education. Daniel M. obtained a Graduate Certificate in Medical Physiology from the University of Florida in 2019 and is currently pursuing a Master's degree in Infectious Diseases from the University of London.